Endothelial <scp>MEMO1</scp> Regulates Angiogenic Signaling in a Model of Retinopathy of Prematurity

Vascular endothelial growth factor (VEGF) is important in both developmental and pathologic angiogenesis in retinopathy of prematurity (ROP). Using a rat model representative of ROP, we found that regulation of VEGF signaling through VEGF receptor 2 (VEGFR2) in retinal microvascular endothelial cells (RMVECs) extended developmental angiogenesis but reduced pathologic angiogenesis, that is, intravitreal neovascularization (IVNV). We identified an adaptor protein, MEMO1, in IVNV in the rat model and tested the hypothesis that MEMO1 in RMVECs was important in IVNV by regulating signaling through VEGFR2. Instead, we found MEMO1 knockdown enhanced phosphorylation of VEGF-induced VEGFR2 and STAT3 and increased wound closure in vitro using cultured human RMVECs. Furthermore, MEMO1 overexpression suppressed VEGF-induced VEGFR2 and STAT3 phosphorylation and dampened VEGF-induced RMVEC wound closure. In contrast, in the absence of VEGF, MEMO1 overexpression promoted RMVEC proliferation in the wound closure assay and AKT phosphorylation, supporting a role for MEMO1 in VEGF-independent angiogenic processes. In vivo, retinal endothelial cell-specific knockdown of MEMO1 in the rat ROP model significantly increased IVNV but did not affect developmental angiogenesis. Our findings support a novel regulatory role for MEMO1 where MEMO1 limits VEGF-driven IVNV and promotes VEGF-independent angiogenic signaling. These results suggest MEMO1 may serve as a protective modulator of pathological angiogenesis in ROP and represent a potential therapeutic target to limit IVNV while preserving physiologic angiogenesis.

Authors

Institutions

Publication Details

Journal
FASEB BioAdvances
Published
2025-09-01
DOI
https://doi.org/10.1096/fba.2025-00146
Primary Topic
Retinopathy of Prematurity Studies
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Endothelial MEMO1 Regulates Angiogenic Signaling in a Model of Retinopathy of Prematurity

Eric Kunz, Arundhathy Suresh, Colin A. Bretz, Aaron B. Simmons et al.
FASEB BioAdvances
Retinopathy of Prematurity Studies
article

Endothelial MEMO1 Regulates Angiogenic Signaling in a Model of Retinopathy of Prematurity

Eric Kunz, Arundhathy Suresh, Colin A. Bretz, Aaron B. Simmons, M. Elizabeth Hartnett, Jasmine Nguyen, Aniket Ramshekar, Bright Asare‐Bediako, Chris Wallace‐Carrete, Chandler J. Zaugg, Haibo Wang
article en

Abstract

Vascular endothelial growth factor (VEGF) is important in both developmental and pathologic angiogenesis in retinopathy of prematurity (ROP). Using a rat model representative of ROP, we found that regulation of VEGF signaling through VEGF receptor 2 (VEGFR2) in retinal microvascular endothelial cells (RMVECs) extended developmental angiogenesis but reduced pathologic angiogenesis, that is, intravitreal neovascularization (IVNV). We identified an adaptor protein, MEMO1, in IVNV in the rat model and tested the hypothesis that MEMO1 in RMVECs was important in IVNV by regulating signaling through VEGFR2. Instead, we found MEMO1 knockdown enhanced phosphorylation of VEGF-induced VEGFR2 and STAT3 and increased wound closure in vitro using cultured human RMVECs. Furthermore, MEMO1 overexpression suppressed VEGF-induced VEGFR2 and STAT3 phosphorylation and dampened VEGF-induced RMVEC wound closure. In contrast, in the absence of VEGF, MEMO1 overexpression promoted RMVEC proliferation in the wound closure assay and AKT phosphorylation, supporting a role for MEMO1 in VEGF-independent angiogenic processes. In vivo, retinal endothelial cell-specific knockdown of MEMO1 in the rat ROP model significantly increased IVNV but did not affect developmental angiogenesis. Our findings support a novel regulatory role for MEMO1 where MEMO1 limits VEGF-driven IVNV and promotes VEGF-independent angiogenic signaling. These results suggest MEMO1 may serve as a protective modulator of pathological angiogenesis in ROP and represent a potential therapeutic target to limit IVNV while preserving physiologic angiogenesis.

FASEB BioAdvancesVol. 7(9)
University of Utah (US), Eye Institute of Utah (US), Stanford University (US)
Research to Prevent Blindness, Ögonfonden, National Institutes of Health, University of North Carolina at Chapel Hill, National Eye Institute
Openalex Percentile: Top 66%
Retinopathy of Prematurity Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.